Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.

  • thorbot@lemmy.worldOP
    link
    fedilink
    English
    arrow-up
    8
    ·
    1 year ago

    Yeah, any news like this is heartening but I always take it with a large grain of salt. I’ve got family member affected by Alzheimer’s so it really hits home.